X4 Pharmaceuticals, Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. X4 is a clinical-stage biopharmaceutical company focused on rare diseases; it has no approved products and has generated no product-sales revenue. Its lead candidate, mavorixafor, is being developed for WHIM syndrome and other chronic neutropenic disorders.
Key financial metrics
| Metric | Q2 2023 | Six months 2023 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $15.6 million | $37.7 million |
| Selling, general and administrative expense | $10.2 million | $17.4 million |
| Net loss | $55.7 million | $79.7 million |
| Net loss per share, basic and diluted | $0.33 | $0.51 |
| Cash used in operating activities | Not separately reported | $47.9 million |
At June 30, cash and cash equivalents were $136.4 million and short-term marketable securities were $4.9 million; restricted cash was a further $1.0 million. Total current assets were $147.6 million and current liabilities $22.3 million. Debt carrying value was $32.6 million, including current and long-term portions. The company reported a $456.5 million accumulated deficit. As a development-stage company, operating margins are not meaningful.
Changes versus the prior comparable period
- Q2 operating expenses rose $5.2 million year over year; first-half expenses rose $13.3 million. R&D increases reflected mavorixafor’s Phase 3 WHIM trial and a $5.0 million accrued Genzyme development milestone.
- Q2 net loss increased from $21.2 million to $55.7 million. The principal unusual item was a $29.9 million noncash loss from the increase in fair value of Class C warrants. First-half warrant remeasurement expense was $24.4 million.
- First-half operating cash use increased from $38.7 million in 2022 to $47.9 million in 2023. Financing cash inflow was $67.2 million, principally reflecting the May private placement.
- In May, X4 raised $65.0 million gross through a private placement of common shares and pre-funded warrants, with approximately $60.7 million net proceeds reported in MD&A. Common shares outstanding rose from 121.7 million at year-end 2022 to 164.4 million at June 30, 2023.
Outlook, financing, and material risks
- Management expected to submit a U.S. NDA for mavorixafor in patients aged 12 and older with WHIM syndrome early in the second half of 2023. The Phase 3 trial met its primary and first key secondary endpoints; additional data reported in May 2023 showed fewer and less severe infections versus placebo.
- The Phase 2 chronic neutropenia trial was enrolling. Preliminary results described increased neutrophil counts, including normalized levels, and reduced G-CSF dosing in some participants. X4 expected to report additional data in Q4 2023 and anticipated starting a pivotal Phase 3 trial in the first half of 2024.
- On August 2, 2023, after quarter-end, X4 amended its Hercules loan: it drew an additional $22.5 million, extended the interest-only period through March 2025, and increased potential facility capacity to $115 million, with further tranches subject to milestones and, in some cases, lender approval. The interest rate remains the greater of 10.15% or prime plus 3.15%. The amendment includes a $20 million minimum-cash covenant through January 31, 2025, followed by revised cash and revenue covenants.
- Management said available cash, securities, and the amended loan were expected to fund operations into 2025, but additional capital would be needed for 2025 and beyond. Based on current projections, the company also disclosed potential difficulty meeting the loan’s minimum-cash covenant in Q1 2025 without additional funding or other qualifying developments. Financing is not assured; failure to comply with loan covenants could trigger default and acceleration.
- Other material risks include regulatory approval and clinical-trial uncertainty, dependence on mavorixafor, limited patient populations and uncertain market size, reliance on single-source manufacturers, competition, reimbursement and pricing uncertainty, and possible dilution or restrictive financing terms. X4 accrued a $5.0 million Genzyme milestone and identified another $7.0 million of regulatory milestones as reasonably possible, but not yet probable, within 10–18 months.
- X4 reported no material legal proceedings and said disclosure controls were effective as of June 30, 2023. Management concluded the company had adequate resources for at least one year after issuance of the statements, while emphasizing the need for future capital.
Investor facts to verify
- Whether the WHIM NDA was submitted on the stated timetable, and subsequent FDA review milestones or requests for additional data.
- Final and updated results from the chronic neutropenia Phase 2 trial, and whether the planned Phase 3 start remains on track.
- Cash burn and liquidity relative to the stated runway, minimum-cash covenant, revenue covenant, and need for financing beyond 2025.
- Availability and conditions of remaining Hercules loan tranches, borrowing costs, repayment obligations, and covenant compliance.
- Potential dilution from outstanding warrants and pre-funded warrants, equity awards, and future capital raises; compare these with the reported 164.4 million common shares outstanding at June 30.
- Potential Genzyme milestone payments and the effect of warrant fair-value changes, which materially affected reported net loss but are noncash remeasurement items.